NU-DUL-1

305607

GENERAL INFORMATION

Description

NU-DUL-1 is a human diffuse large B-cell lymphoma (DLBCL) cell line derived from an adult patient. This cell line is notable for its utility in studying the molecular and cellular mechanisms underlying non-Hodgkin lymphoma, particularly the aggressive diffuse large B-cell subtype. NU-DUL-1 cells exhibit hallmark features of DLBCL, including abnormal B-cell differentiation and dysregulated signaling pathways, making them a relevant in vitro model for lymphoma research.
NU-DUL-1 cells grow in suspension, displaying a round, single-cell morphology typical of lymphoblastoid cells. They carry genetic abnormalities frequently associated with diffuse large B-cell lymphoma, providing an important tool for examining oncogenic signaling pathways, drug resistance mechanisms, and potential therapeutic targets. Researchers often use NU-DUL-1 cells to investigate the efficacy of chemotherapeutic agents and monoclonal antibodies, as well as the molecular responses to targeted therapies.
This cell line is well-suited for studies on tumor immunology, as it retains characteristics relevant to immune evasion and interactions with the tumor microenvironment. The NU-DUL-1 cell line provides a robust platform for preclinical research, offering insights into DLBCL biology and contributing to the development of novel therapeutic strategies for this aggressive lymphoma subtype.

Tissue	Brain
Disease	Diffuse large B-cell lymphoma

Synonyms

- NUDUL-1
- NUDUL1

CLASSIFICATION

Organism	Human
Sex	Male
Growth properties	Suspension
Biosafety level	1

CHARACTERISTICS

Morphology	Polymorphic
Cell type	Lymphocyte

IDENTIFIERS

Citation

NU-DUL-1 (Cytion catalog number 305607)

NCBI TaxID	9606
Cellosaurus	CVCL_1877

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB

EXPRESSION AND SUSCEPTIBILITY

Antigen expression

CD3 -, CD10 +, CD13 -, CD19 +, CD20 +, CD34 -, CD37 +, CD38 +, cyCD79a +, CD138 -, HLA-DR +, sm/cyIgG +, sm/cyIgM -, sm/cykappa -, sm/cylambda +

Mutational profile

Mutation: KRAS, p.Asp119Asn (c.355G>A), Heterozygous; Mutation: TP53, p.Val143Met (c.427G>A), Heterozygous; Mutation: TP53, p.Arg248Gln (c.743G>A), Heterozygous

HANDLING AND CULTURE

Culture medium

RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)

Incubation atmosphere	37°C, 5% CO_2, humidified atmosphere.

Supplements

Supplement the medium with 10% FBS

Fluid renewal	2 to 3 times per week

Thawing and culturing

Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.
Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.
For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.
Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.
Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.
Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.
Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.
Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

QUALITY CONTROL AND CRYOPRESERVATION

Sterility

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.
To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

Freeze medium	As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.

Storage conditions

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Shipping conditions

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

DONOR

Donor age	43 years

Ethnicity	Caucasian

LEGAL AND SAFETY

Safety precautions

When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments.

Warranty

At Cytion, we stand behind the quality and viability of our products.
We guarantee that our cells will be viable at the start of culture for
60 days after shipment from our facilities.
We assure that all materials conform to the specifications described in the
Certificate of Analysis and/or Product Sheet.
For full details, please refer to our
Warranty Statement.

Material Transfer Agreement required	Yes